These results indicate that anti-proteolytic PD-1/PD-L1 polypeptide inhibitors can be administered orally in the treatment of gastrointestinal tumors, which opens up new prospects for the development of oral drugs in tumor immunotherapy. The gene discussed is CD274; the disease is neoplasm.